LWM
GSK icon

Laidlaw Wealth Management’s GSK GSK Stock Holding History

Laidlaw Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,603
Closed -$309K – 409
2021
Q4 		$309K Buy
5,603
+835
+18% +$43.4K 0.05% 304
2021
Q3 		$228K Buy
+4,768
New +$239K 0.06% 220

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Laidlaw Wealth Management's GSK Position: Q1 2022 in Review

Laidlaw Wealth Management sold out of GSK (GSK) in Q1 2022, closing a stake of 5,603 shares — an estimated $309K sold.

Laidlaw Wealth Management first reported a position in GSK in Q3 2021 and held it in 2 quarters. The position peaked at $309K in Q4 2021. 929 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

  • Laidlaw Wealth Management reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
  • Laidlaw Wealth Management sold 5,603 GSK shares in Q1 2022, an estimated $309K.
  • Laidlaw Wealth Management first reported a position in GSK in Q3 2021 and held it in 2 quarters.
  • Laidlaw Wealth Management's GSK position peaked at $309K in Q4 2021.
  • 929 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Laidlaw Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.